Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Authors
Keywords
-
Journal
CIRCULATION
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-08-30
DOI
10.1161/circulationaha.121.056810
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER
- (2021) Filipe Cirne et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer
- (2021) Lova Sun et al. JAMA Network Open
- New Approaches to Conducting Randomized Controlled Trials
- (2020) Alexander C. Fanaroff et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study
- (2020) Darryl P. Leong et al. JOURNAL OF UROLOGY
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis
- (2020) Valentina Perrone et al. Therapeutics and Clinical Risk Management
- Randomized Trials Versus Common Sense and Clinical Observation
- (2020) Alexander C. Fanaroff et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer
- (2020) Alicia K. Morgans et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice
- (2020) Patrick Davey et al. WORLD JOURNAL OF UROLOGY
- Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases
- (2020) Gincy George et al. INTERNATIONAL JOURNAL OF CANCER
- New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes
- (2019) Vincenzo Di Nunno et al. Clinical Genitourinary Cancer
- Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease
- (2019) David Margel et al. JOURNAL OF UROLOGY
- A population-based study of cardiovascular disease mortality risk in US cancer patients
- (2019) Kathleen M Sturgeon et al. EUROPEAN HEART JOURNAL
- The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Roberto Iacovelli et al. Clinical Genitourinary Cancer
- Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis
- (2018) Kevin T. Nead et al. UROLOGY
- Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes
- (2018) Marie C. Hupe et al. Frontiers in Oncology
- Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data
- (2017) Lucie-Marie Scailteux et al. EUROPEAN JOURNAL OF CANCER
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
- (2016) Alessandro Sciarra et al. MEDICINE
- Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE −/− mice
- (2016) Anki Knutsson et al. Scientific Reports
- Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
- (2015) Cecilia Bosco et al. EUROPEAN UROLOGY
- Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial.
- (2015) Celestia S. Higano et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
- (2015) Sean O'Farrell et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms
- (2015) Åsa Tivesten et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies
- (2014) Jinsheng Zhao et al. PLoS One
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
- (2013) Peter C. Albertsen et al. EUROPEAN UROLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care
- (2012) Thomas J. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen deprivation and thromboembolic events in men with prostate cancer
- (2011) Behfar Ehdaie et al. CANCER
- Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix
- (2011) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk
- (2010) Glenn N. Levine et al. CIRCULATION
- Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer
- (2010) Shabbir M.H. Alibhai et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started